2 drug(s) with this reaction
1,262 total reports
Osteoporosis has been reported as an adverse reaction across 2 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,262 adverse event reports mention osteoporosis in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with osteoporosis, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have osteoporosis listed in their FDA adverse event reports, sorted by report count:
In addition to osteoporosis, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
2 drug(s) manufactured by Abbvie Inc have osteoporosis listed in their FDA adverse event reports: RITONAVIR, LOPINAVIR AND RITONAVIR.
There are a combined 1,262 reports of osteoporosis across 2 Abbvie Inc drug(s) in the FDA adverse event database.